Development and validation of discriminating method of dissolution for fosamprenavir tablets based on in vivo data

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 3, 2011, Pages 439-444

  Rossi, Rochele C ^a   Dias, Carolina L ^a   Bajerski, Lisiane ^a   Bergold, Ana Maria ^a   Fröehlich, Pedro E ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Dissolution; Fosamprenavir; In vitro in vivo correlation; Validation

Indexed keywords

FOSAMPRENAVIR;

ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG SPECIFICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; ROTATION; TABLET FORMULATION; VALIDATION PROCESS;

CARBAMATES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; HIV PROTEASE INHIBITORS; HUMANS; PHOSPHORIC ACID ESTERS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOFTWARE; SOLUBILITY; SULFONAMIDES; TABLETS;

EID: 78149499337     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.09.004     Document Type: Article

References (25)

1. Krämer J., Grady L.T., Gajendran J. Historical development of dissolution testing. Pharmaceutical Dissolution Testing 2005, 1-38. Taylor & Francis Group, New York. J. Dressman, J. Krämer (Eds.).
2. US Pharmacopeial Forum, Pharmacopeial Previews, vol. 30, 2004, pp. 351-363.
3. FDA Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms 1997, Food and Drug Administration, Rockville, MD.
4. FDA Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of in vitro/in vivo Correlations 1997, Food and Drug Administration, Rockville, MD.
5. Dressman J.B., Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci. 2000, 11:73-80.
6. Uppoor V.R.S. Regulatory perspectives on in vitro (dissolution)/in vivo (bioavailability) correlations. J. Control. Release 2001, 72:127-132.
7. J.M. Cardot, E. Beyssac, M. Alric, In vitro-in vivo correlation: importance of dissolution in IVIVC, Dissolution Technologies, 2007, pp. 15-19.
8. Corbett A.H., Kashuba A.D.M. Fosamprenavir Vertex Pharmaceuticals/GlaxoSmithKline. Curr. Opin. Investig. Drugs 2007, 3:384-390.
9. Falcoz C., Jenkins J.M., Bye C., Hardman T.C., Kenney K.B., Studenberg S., Fuder H., Prince W.T.J. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. Clin. Pharmacol. 2002, 42:887-898.
10. Furfine E.S., Baker C.T., Hale M.R., Reynolds D.J., Salisbury J.A., Searle A.D., Studenberg S.D., Todd D., Tung R.D., Spaltenstein A. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob. Agents Chemother. 2004, 48:791-798.
11. FDA, Food and Drug Administration Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations 2009, http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm%3FAppl_No=021548%26TABLE1=OB_Rx.
12. EMEA, European Medicines Agency, 2009, http://www.emea.europa.eu/humandocs/PDFs/EPAR/telzir/H-534-PI-en.pdf.
13. Amidon G.L., Lennernäs H., Shah V.P., Crison J.R. A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12:413-420.
14. FDA, Food and Drug Administration, http://www.accessdata.fda.gov/scripts/cder/dissolution.
15. Wood R., Arasteh K., Stelbrink H., Teofilo E., Raffi F., Pollard R., Yeo J., Wire M.b. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 2004, 48:116-123.
16. Shargel L., Yu A.B.C. Applied Biopharmaceutical and Pharmacokinetics 2005, Appleton & Lange, USA, pp. 267-269. 5th ed.
17. US Pharmacopoeia NF-25 <1092> The Dissolution Procedure: Development and Validation 2009, US Pharmacopoeial Convention, Rockville, MD. 32nd ed.
18. ICH, Validation of analytical procedures: text and methodology (Q2R1), in: International Conference on Harmonization, Geneva, 2005.
19. Kibbe A.H. Hand Book of Pharmaceutical Excipients 2000, Pharmaceutical Press, Washington, 665 pp. 3rd ed.
20. Costa P., Lobo J.M.S. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sci. 2001, 13:123-133.
21. Freitag G. Guidelines on dissolution profile comparison. Drug Inf. J. 2001, 35:865-874.
22. Shah V.P., Polli J.E. Methods to compare dissolution profiles. Drug Inf. J. 1996, 30:1113-1120.
23. Emami F. In vitro-in vivo correlation: from theory to applications. J. Pharm. Pharmaceut. Sci. 2006, 9:169-189.
24. Brown C.K., Chokshi H.P., Nickerson B., Reed R.A., Rohrs B.R., Shah P.A. Acceptable analytical practices for dissolution testing of poorly soluble compounds. Pharm. Technol. 2004, 56-65.
25. Yoshioka S., Stella V.J. Stability of Drugs and Dosage Forms 2002, Kluwer Academic Publishers, New York.